AbbVie Inc. vs Celgene
Market value, revenue, profit, valuation and financial strength side by side, each from the company's own filings or market data, with its date.
Market cap history
● AbbVie Inc.● Celgene
Revenue by fiscal year
US$ billions, as reported in each year's annual results.
Side by side
| Measure | AbbVie Inc. ABBV · #26 in the world | Celgene CELG |
|---|---|---|
| Profile | ||
| Country | 🇺🇸 USA | 🇺🇸 USA |
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceutical | — |
| Founded | 2013 | 1986 |
| Size | ||
| Market cap | $514.0 B | — |
| Revenue | $61.2 B | — |
| Net income | $4.2 B | — |
| Employees | 57,000 | — |
| Valuation | ||
| P/E ratio | 49.7× | — |
| Price to sales | 7.8× | — |
| Free cash flow yield | 3.5% | — |
| Profitability | ||
| Gross margin | 70.2% | — |
| Operating margin | 24.6% | — |
| Net margin | 6.9% | — |
| Return on invested capital | 16.0% | — |
| Growth | ||
| Revenue growth | 8.6% | — |
| Revenue growth, 3 years a year | 1.8% | — |
| Earnings per share growth | -1.3% | — |
| Financial strength | ||
| Interest cover | 5.2× | — |
| Cash | ||
| Free cash flow margin | 29.1% | — |
| Shareholder returns | ||
| Dividend yield | 2.3% | — |
| Shareholder yield | 2.5% | — |
| Strength scores | ||
| Piotroski F-score | 8 of 9 | — |
| Altman Z-score zone | grey | — |
| Data as of | Market cap Oct 2026; ratios FY2025 | Market cap — |
▲ marks the better of the two where higher or lower is better; size and valuation multiples are marked for neither
More about AbbVie Inc.
More about Celgene
Sources#
Every figure on this page comes from these, with the date shown next to it.